• Editas Medicine Inc EDIT.OQ reported a quarterly adjusted loss of 92 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -76 cents. The mean expectation of eleven analysts for the quarter was for a loss of 59 cents per share. Wall Street expected results to range from -84 cents to -41 cents per share.

• Revenue rose 310.4% to $4.66 million from a year ago; analysts expected $706.00 thousand.

• Editas Medicine Inc's reported EPS for the quarter was a loss of 92 cents​.

• The company reported a quarterly loss of $76.09 million.

• Editas Medicine Inc shares had risen by 25.0% this quarter and gained 14.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 14.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 8 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Editas Medicine Inc is $3.50

This summary was machine generated from LSEG data May 12 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)